Preliminary communicationAn open-label trial of olanzapine for corticosteroid-induced mood symptoms
Introduction
Since their introduction in the 1950s, corticosteroids have been widely prescribed for a variety of medical conditions such as asthma, rheumatic illnesses, transplant rejection, and dermatological disorders. Case reports of psychiatric side effects including mania, depression, mood lability, or even psychosis during corticosteroid therapy are numerous (Brown and Suppes, 1998, Brown et al., 1999a, Kaufmann, 1982, Wada et al., 2000, Wada et al., 2001a). The psychiatric effects of long-term corticosteroid therapy are not well investigated; however, short-term therapy appears to be primarily associated with manic or hypomanic, rather than depressive, symptoms or psychosis (Brown et al., 2002).
From the time of these first case reports, various classes of psychotropic medications have been used in an effort to prevent or treat corticosteroid-induced psychiatric syndromes. Only one controlled clinical trial has been conducted in patients with psychiatric symptoms secondary to corticosteroids. In this study, Falk et al. (1979) reported that lithium pretreatment might prevent corticosteroid-induced mood symptoms. While 14% of patients receiving corticotropin therapy suffered from mood symptoms, none of the patients receiving corticotropin following lithium pretreatment had a mood disturbance. Case reports suggest that lithium and other mood stabilizers including lamotrigine, carbamazepine, gabapentin, and valproic acid may effectively treat or prevent corticosteroid-induced mood symptoms after their development (Brown, 2003, Brown et al., 2003, Ginsberg and Sussman, 2001, Kahn et al., 1988, Preda et al., 1999, Wada et al., 2001b). Another class of medications that may effectively treat psychiatric symptoms associated with corticosteroids is antipsychotics, including both traditional neuroleptics (Ahmad and Rasul, 1999) and the newer atypical agents (Brown et al., 1999b, DeSilva et al., 2002, Goldman and Goveas, 2002, Kramer and Cottingham, 1999). Our group reported a case wherein a patient with depressed mood, insomnia, and suicidal ideation—all attributed to chronic corticosteroid therapy—responded with almost complete amelioration of these symptoms following the initiation of olanzapine therapy at 2.5 mg/day (Brown et al., 1999b). Recently, Goldman and Goveas (2002) reported a case series of five patients with a variety of symptoms including psychosis, anxiety, and mood disturbance, who responded at 2.5–15 mg/day. As symptoms associated with corticosteroids frequently include manic/hypomanic or mixed symptoms and because olanzapine is Food and Drug Administration (FDA)-approved for mania, we wanted to explore the efficacy of olanzapine in a larger sample of patients with prednisone-induced manic symptoms. In the study reported here, we provide data from an open-label trial of olanzapine in 12 patients with corticosteroid-induced manic or mixed symptoms.
Section snippets
Methods
Twelve outpatients between the ages of 18 and 65 years from University of Texas Southwestern Medical Center-affiliated clinics, or recruited from offsite flyer postings, who were receiving corticosteroids and experiencing clinically significant manic or mixed symptoms (defined as a Young Mania Rating Scale (YMRS) (Young et al., 1978) score≥10) related to corticosteroid use were included. This YMRS cutoff was selected to include people with clinically significant manic or hypomanic symptoms
Results
Demographic characteristics of the participants are provided in Table 1. All the patients met diagnostic criteria based on the SCID for a prednisone-induced mood disorder, with five having manic features and seven having mixed features. Eleven of 12 participants completed the study. One participant discontinued from the study on the third visit while receiving olanzapine at 7.5 mg/day due to minimal improvement in irritability and insomnia.
Patients were receiving corticosteroids for the
Discussion
These findings demonstrate significant decreases in YMRS, HRSD, and BPRS scores during olanzapine treatment in patients with corticosteroid-induced manic or mixed symptoms. The results are consistent with anecdotal reports on the efficacy of olanzapine for mood symptoms with corticosteroids (Brown et al., 1999b, Goldman and Goveas, 2002).
Olanzapine was also well tolerated in this sample. As expected, measures of extrapyramidal symptom severity did not significantly change (Leucht et al., 1999).
References (30)
- et al.
Steroid-induced psychosis treated with haloperidol in a patient with active chronic obstructive pulmonary disease
Am. J. Obstet. Gynecol.
(1999) - et al.
Olanzapine treatment of corticosteroid-induced mood disorders
Psychosomatics
(2002) - et al.
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
Schizophr. Res.
(1999) - et al.
Mechanisms involved in the side effects of glucocorticoids
Pharmacol. Ther.
(2002) - et al.
Corticosteroid-induced psychotic and mood disorders: diagnosis defined by DSM-IV and clinical pictures
Psychosomatics
(2001) - et al.
Carbamazepine treatment of corticosteroid-induced mood disorder
J. Affect. Disord.
(2001) - et al.
Weight gain associated with atypical antipsychotic drugs: mechanisms and management
Expert Rev. Neurotherapeutics
(2003) A rating scale for drug-induced akathisia
Br. J. Psychiatry
(1989)Management of psychiatric side effects associated with corticosteroids
Expert Rev. Neurotherapeutics
(2003)- et al.
Effect of lamotrigine on mood and cognition in patients receiving chronic exogenous corticosteroids
Psychosomatics
(2003)